LONDON: OptiBiotix Health plc (AIM: OPTI), a UK-based life sciences company focused on microbiome modulation and healthy sugar alternatives, reported a 35% increase in annual revenue for the year ending Dec. 31, 2024, signaling a strong turnaround bolstered by international expansion and ecommerce growth. Revenue rose to £870,000 from £644,000 in 2023, driven by increased…
LONDON: OptiBiotix Health plc (AIM: OPTI) has launched a new product containing SlimBiome® in partnership with Natural Health Trends Corp (NASDAQ: NHTC), marking its latest expansion into the U.S. and Asian markets. Natural Health Trends, a NASDAQ-listed international direct-selling and e-commerce company, has introduced TwinSlim Tomato Soup, a formulation developed by OptiBiotix for the Chinese…
LONDON, UK: OptiBiotix Health plc (AIM: OPTI), a life sciences business, intends to seek admission of its wholly owned subsidiary, ProBiotix Health Limited , onto the AQSE Growth Market with an associated fund raise and distribution in specie. Key points • Proposed £2.5m fundraise by ProBiotix Health by way of placing and subscription. • EIS/VCT qualifying. • A distribution in specie of ProBiotix Health…
LONDON: OptiBiotix Health, a life sciences business, has entered into an agreement with a US company for the purpose of large scale manufacture and commercialisation of a number of SweetBiotix products, a news release said. The agreement grants the US Company an exclusive worldwide license in return for it bearing the costs relating to product…